Adocia SA (EPA:ADOC)

France · Delayed Price · Currency is EUR

2.430

+0.070 (2.97%)

Oct 22, 2026, 5:35 PM CEST

Adocia Earnings Call Transcripts

Fiscal Year 2026

Study result
Phase III results for BC Lispro in type 2 diabetes showed non-inferior HbA1c overall, superior outcomes in metformin users or those with lower baseline HbA1c, improved postprandial glucose, and a favorable safety profile. Its faster onset and shorter duration than current ultra-rapid insulins support broader adoption and commercialization.

Read full transcript →

Press release
Slides